HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNC Supply Chain Reform Pays Dividends In DoJ Settlement From DMAA Investigation

This article was originally published in The Rose Sheet

Executive Summary

DoJ announces a "non-prosecution agreement" that requires GNC to pay $2.25m and to cooperate in dietary supplement market investigations conducted by FDA and other federal agencies, including the current litigation against USPlabs.

You may also be interested in...



Hi-Tech CEO Wheat Arrested In FDA Investigation Of Steroid-Spiked Supplements

Hi-Tech Pharmaceuticals CEO Jared Wheat and an associate face 18 criminal charges in federal court alleging they falsified FDA documents and distributed as supplements products containing steroid ingredient. Wheat is appealing the indictment to federal circuit court.

S.K. Labs VP Imprisoned Before Trial On Charges Linked To USPlabs

S.K. Labs VP Sitesh Patel was sentenced for his conviction in an April trial of single counts of conspiracy to defraud FDA and conspiracy to commit mail fraud and three counts of mail fraud. He faced up to 85 years in prison and up to $1.25m in fines.

Supplement Sector Regulatory Milestones: Senators' Enforcement Push, GNC Supply Chain Guidelines

Former FDA OCI Director George Karavetsos says GNC's supply chain guidelines for its vendors is the industry standard, while Sens. Hatch and Heinrich exceeded all standards by recommending DoJ get tougher on firms violating FDA supplement product regulations,

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS108734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel